Therefore, to identify a causal relationship between these biomarkers, genetic and multicenter studies on large cohort of patients are necessary to further specify and validate the findings of the current study and to confirm the prediction accuracy of adropin and afamin in the CKD population, along with other clinical factors and diagnostic techniques. The gene discussed is AFM; the disease is chronic kidney disease.